ARDX DEADLINE: Levi & Korsinsky Reminds Ardelyx, Inc. Investors of Upcoming Securities Class Action Deadline
Alert: Claims focus on alleged misrepresentations about payer utilization management and prescription pull-through, which allegedly slowed new-patient starts for IBSRELA while Ardelyx reaffirmed $240 million to $250 million in 2025 sales guidance. NEW YORK, Oct. 14, 2026 /PRNewswire/ --...
Covered in this story
Call it yourself
No calls on $ARDX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ardelyx Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.